icon
icon
icon
icon
Upgrade
icon

Astellas (ALPMY.US) CLDN18.2 antibody approved for first-line treatment of advanced cancer

AInvestSaturday, Oct 19, 2024 8:20 pm ET
1min read

On October 20, Astellas (ALPMY.US) announced that the U.S. FDA has approved Vyloy (zolbetuximab), its anti-Claudin18.2 (CLDN18.2) antibody, in combination with a chemotherapy regimen containing fluoropyrimidine and platinum, for the first-line treatment of adult patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are positive for CLDN18.2 as determined by an FDA-approved test. Notably, this approval is three weeks ahead of the original PDUFA date of November 9. According to the press release, Vyloy is the first FDA-approved CLDN18.2-targeted therapy. Gastric cancer is one of the most common cancers worldwide and is also one of the leading causes of cancer deaths. Adenocarcinoma is the major histological subtype of gastric cancer, accounting for over 90% of reported cases worldwide. According to statistics, more than 70% of gastric cancer patients are diagnosed at an advanced stage, and they urgently need innovative therapies. Claudin is an important protein in the tight junction of normal tissues, with four transmembrane domains, which regulates the processes of cell paracellular permeability and conductivity. CLDN18.2 is highly expressed in digestive tract cancers, including gastric cancer. Therefore, CLDN18.2 is an effective target for the treatment of gastric cancer, pancreatic cancer, etc.

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.